Hemiasterlin derivative (R)(S)(S)-BF65 and Akt inhibitor MK-2206 synergistically inhibit SKOV3 ovarian cancer cell growth

被引:7
|
作者
Lai, Wei-Ting [1 ]
Cheng, Kai-Lin [1 ]
Baruchello, Riccardo [2 ]
Rondanin, Riccardo [2 ]
Marchetti, Paolo [2 ]
Simoni, Daniele [2 ]
Lee, Ray M. [3 ]
Guh, Jih-Hwa [1 ]
Hsu, Lih-Ching [1 ]
机构
[1] Natl Taiwan Univ, Sch Pharm, 33 Linsen S Rd, Taipei 10050, Taiwan
[2] Univ Ferrara, Dept Pharmaceut Sci, Via Fossato di Mortara 17-19, I-44121 Ferrara, Italy
[3] Truswork LLC, Short Hills, NJ USA
关键词
Hemiasterlin derivative (R)(S)(S)-BF65; Akt inhibitor MK-2206; MAPK and Akt signaling pathways; Ovarian cancer; SIGNALING PATHWAYS; IN-VITRO; APOPTOSIS; CYTOTOXICITY; MICROTUBULES; ACTIVATION; TARGET; AGENTS; ANALOG; DAMAGE;
D O I
10.1016/j.bcp.2016.06.010
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We reported previously that a hemiasterlin derivative BF65 is a potent anticancer agent that can inhibit microtubule assembly. Here we show that a more potent stereospecific diastereomer (R)(S)(S)-BF65 can synergize with an allosteric Akt inhibitor MK-2206 to suppress the growth of SKOV3 ovarian cancer cells with constitutively active Akt. (R)(S)(S)-BF65 induced mitotic arrest and MK-2206 caused G0/G1 arrest, while the combination of both induced simultaneous G0/G1 and G2/M cell cycle arrest. (R)(S)(S)-BF65 induced phosphorylation and inactivation of Bcl-2, and downregulated Mcl-1, consequently may lead to apoptosis. (R)(S)(S)-BF65 inhibited mitogen-activated protein kinases (MAPKs), which may stimulate cell proliferation upon activation. (R)(S)(S)-BF65 also induced DNA damage after long-term treatment. MK-2206 is known to inhibit phosphorylation and activation of Akt and suppress cancer cell growth. The combination of (R)(S)(S)-BF65 and MK-2206 also inhibited the Akt pathway. Interestingly, MK-2206 upregulated Bcl-2 and induced activation of MAPKs in SKOV3 cells; however, when combined with (R)(S)(S)-BF65, these prosurvival effects were reversed. The combination also more significantly decreased Mcl-1 protein, increased PARP cleavage, and induced gamma-H2AX, a DNA damage marker. Remarkably, MK-2206 enhanced the microtubule depolymerization effect of (R)(S)(S)-BF65. The combination of (R)(S)(S)-BF65 and MK-2206 also markedly inhibited cell migration. Thus, MK-2206 synergizes with (R)(S)(S)-BF65 to inhibit SKOV3 cell growth via downregulating the Akt signaling pathway, and enhancing the microtubule disruption effect of (R)(S)(S)-BF65. (R)(S)(S)-BF65 in turn suppresses Bcl-2 and MAPKs induced by MK-2206. (R)(S)(S)-BF65 and MK-2206 compensate each other leading to increased apoptosis and enhanced cytotoxicity, and may also suppress cancer cell invasion. (C) 2016 Elsevier Inc. All rights reserved.
引用
收藏
页码:12 / 23
页数:12
相关论文
共 10 条
  • [1] Combination of hemiasterlin derivative (R)(S)(S)-BF65 and PI3K/mTOR dual inhibitor NVP-BEZ235 as a new strategy to inhibit ovarian cancer growth and metastasis
    Su, Po-Chia
    Huang, Tzu-En
    Hsu, Lih-Ching
    CANCER RESEARCH, 2019, 79 (13)
  • [2] Human Wharton's Jelly Stem Cell (hWJS']JSC) Extracts Inhibit Ovarian Cancer Cell Lines OVCAR3 and SKOV3 in vitro by Inducing Cell Cycle Arrest and Apoptosis
    Kalamegam, Gauthaman
    Sait, Khalid Hussein Wall
    Ahmed, Farid
    Kadam, Roaa
    Pushparaj, Peter Natesan
    Anfinan, Nisreen
    Rasoo, Mahmood
    Jamal, Mohammad Sarwar
    Abu-Elmagd, Muhammed
    Al-Qahtani, Mohammed
    FRONTIERS IN ONCOLOGY, 2018, 8
  • [3] Lysine-Specific Demethylase 1 (LSD1) Inhibitor S2101 Induces Autophagy via the AKT/mTOR Pathway in SKOV3 Ovarian Cancer Cells
    Feng, Shujun
    Jin, Ye
    Cui, Mengjiao
    Zheng, Jianhua
    MEDICAL SCIENCE MONITOR, 2016, 22 : 4742 - 4748
  • [4] Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005)
    Ramanathan, Ramesh K.
    McDonough, Shannon L.
    Kennecke, Hagen F.
    Iqbal, Syma
    Baranda, Joaquina C.
    Seery, Tara E.
    Lim, Howard J.
    Hezel, Aram F.
    Vaccaro, Gina M.
    Blanke, Charles D.
    CANCER, 2015, 121 (13) : 2193 - 2197
  • [5] A phase II study of MK-2206, an allosteric inhibitor of AKT as second-line therapy for advanced gastric and gastroesophageal junction (GEJ) cancer: A SWOG Cooperative Group trial (S1005).
    Ramanathan, Ramesh K.
    McDonough, Shannon L.
    Kennecke, Hagen F.
    Iqbal, Syma
    Baranda, Joaquina Celebre
    Seery, Tara Elisabeth
    Lim, Howard John
    Hezel, Aram F.
    Vaccaro, Gina M.
    Blanke, Charles David
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] Corrigendum: Human Wharton's Jelly stem cell (hWJS']JSC) extracts inhibit ovarian cancer cell lines OVCAR3 and SKOV3 in vitro by inducing cell cycle arrest and apoptosis (vol 8, 592, 2018)
    Kalamegam, Gauthaman
    Sait, Khalid Hussein Wali
    Ahmed, Farid
    Kadam, Roaa
    Pushparaj, Peter Natesan
    Anfinan, Nisreen
    Rasool, Mahmood
    Jamal, Mohammad Sarwar
    Abu-Elmagd, Muhammed
    Al-Qahtani, Mohammed
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [7] S-Phase Cell Cycle Arrest, Apoptosis, and Molecular Mechanisms of Aplasia Ras homolog Member I-Induced Human Ovarian Cancer SKOV3 Cell Lines
    Zhu, Qiaoying
    Hu, Jianming
    Meng, Huijuan
    Shen, Yufei
    Zhou, Jinhua
    Zhu, Zhihong
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (04) : 629 - 634
  • [8] Antidiabetic drug metformin mitigates ovarian cancer SKOV3 cell growth by triggering G2/M cell cycle arrest and inhibition of m-TOR/PI3K/Akt signaling pathway
    Fu, Y. -L.
    Zhang, Q. -H.
    Wang, X. -W.
    He, H.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2017, 21 (05) : 1169 - 1175
  • [9] S100A14 plays an important role in cell growth and metastasis of epithelial ovarian cancer through PI3K-AKT pathway
    Cho, Hanbyoul
    Lee, Maria
    Shin, Ha-Yeon
    Yang, Wookyeom
    Lee, Eun-ju
    Kwon, Hyunja
    Kim, Sol
    Kim, Jae-Hoon
    CANCER RESEARCH, 2014, 74 (19)
  • [10] Surface marker and gene expression profiling of tumors from PDX models of small cell lung cancer with varying sensitivity to growth inhibition by the p70S6K/AKT1/3 inhibitor M2698
    Hahn, Friedrich
    Porter, Warren
    Snowden, Eileen
    Ferguson, Mitchell
    Tong, Frances
    Dillmore, William S.
    Clark, Anderson
    Zhang, Hong
    Blaesius, Rainer
    CANCER RESEARCH, 2018, 78 (13)